Zacks Investment Research upgraded shares of BIOLASE TECH (BIOL) from UNDERPERFORM to NEUTRAL on November 27, 2012, with a target price of $1.90.
Biolaw Technology, Inc. is the world's leading dental laser company, is a medical technology company that develops, manufactures and markets lasers and related products focused on technologies that advance the practice of dentistry and medicine. The Company's products incorporate patented and patent pending technologies designed to provide clinically superior performance with less pain and faster recovery times. BIOLASE's principal products are dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications. Other products under development address ophthalmology and other medical and consumer markets.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on BIOLASE TECH (BIOL),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment